These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22394596)

  • 61. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
    O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
    Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
    Sinan Dal M; Merdin A; Erkurt MA; Ekinci Ö; Albayrak M; Kabukcu Hacıoglu S; Kaya A; Dogu MH; Hindilerden F; Sarici A; Merter M; Reis Aras M; Akgun Caglıyan G; Kizil Cakar M; Aydogdu I; Kuku I; Korkmaz S; Ulas T; Eser B; Altuntas F
    J BUON; 2021; 26(4):1536-1539. PubMed ID: 34565016
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
    Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
    Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
    Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
    J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
    Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 71. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
    Mukai M; Mould D; Maeda H; Narushima K; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation.
    Frederiks AJ; Creeper KJ; Spagnolo DV; Cannell P; Radeski D
    Australas J Dermatol; 2021 Aug; 62(3):e400-e403. PubMed ID: 34028795
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
    Querfeld C; Kuzel TM; Kim YH; Porcu P; Duvic M; Musiek A; Rook AH; Mark LA; Pinter-Brown L; Hamid O; Lin B; Bian Y; Boye M; Day JM; Rosen ST
    Leuk Lymphoma; 2011 Aug; 52(8):1474-80. PubMed ID: 21649541
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma.
    Argiris A; Heald P; Kuzel T; Foss FM; DiStasio S; Cooper DL; Arbuck S; Murren JR
    Invest New Drugs; 2001; 19(4):321-6. PubMed ID: 11561692
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
    Afifi S; Mohamed S; Zhao J; Foss F
    Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
    [No Abstract]   [Full Text] [Related]  

  • 80. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.